These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 25741970)

  • 21. Antiretroviral therapy responses among children attending a large public clinic in Soweto, South Africa.
    Meyers TM; Yotebieng M; Kuhn L; Moultrie H
    Pediatr Infect Dis J; 2011 Nov; 30(11):974-9. PubMed ID: 21734620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
    De Luca A; Cozzi-Lepri A; Antinori A; Zaccarelli M; Bongiovanni M; Di Giambenedetto S; Marconi P; Cicconi P; Resta F; Grisorio B; Ciardi M; Cauda R; Monforte Ad; ; ; ;
    Antivir Ther; 2006; 11(5):609-18. PubMed ID: 16964829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Lopinavir/Ritonavir and Efavirenz-Based Antiretroviral Therapy on the Lipid Profile of Chinese HIV/AIDS Treatment-Naïve Patients in Beijing: A Retrospective Study.
    Dai L; Liu A; Zhang H; Wu H; Zhang T; Su B; Shao Y; Li J; Ye J; Scott SR; Mahajan SD; Schwartz SA; Yu H; Sun L
    Curr HIV Res; 2019; 17(5):324-334. PubMed ID: 31654514
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful treatment with atazanavir and lopinavir/ritonavir combination therapy in protease inhibitor-susceptible and protease inhibitor-resistant HIV-infected patients.
    Gilliam BL; Chan-Tack KM; Qaqish RB; Rode RA; Fantry LE; Redfield RR
    AIDS Patient Care STDS; 2006 Nov; 20(11):745-59. PubMed ID: 17134349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.
    Prosperi MC; Zazzi M; Punzi G; Monno L; Colao G; Corsi P; Di Giambenedetto S; Meini G; Ghisetti V; Bonora S; Pecorari M; Gismondo MR; Bagnarelli P; Carli T; De Luca A;
    J Med Virol; 2010 Dec; 82(12):1996-2003. PubMed ID: 20981785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice.
    Lambert-Niclot S; Masquelier B; Cohen Codar I; Soulie C; Delaugerre C; Morand-Joubert L; Charpentier C; Ferre V; Plantier JC; Montes B; Carret S; Perrot V; Peytavin G; Costagliola D; Calvez V; Marcelin AG;
    J Antimicrob Chemother; 2012 Oct; 67(10):2487-93. PubMed ID: 22733652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
    Lathouwers E; De Meyer S; Dierynck I; Van de Casteele T; Lavreys L; de Béthune MP; Picchio G
    Antivir Ther; 2011; 16(1):99-108. PubMed ID: 21311113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monotherapy with Lopinavir/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study).
    Nunes EP; Santini de Oliveira M; Merçon M; Zajdenverg R; Faulhaber JC; Pilotto JH; Ribeiro JE; Norton M; Schechter M
    HIV Clin Trials; 2009; 10(6):368-74. PubMed ID: 20133267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The level of persistent HIV viremia does not increase after successful simplification of maintenance therapy to lopinavir/ritonavir alone.
    McKinnon JE; Arribas JR; Pulido F; Delgado R; Mellors JW
    AIDS; 2006 Nov; 20(18):2331-5. PubMed ID: 17117019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.
    Bunupuradah T; Chetchotisakd P; Ananworanich J; Munsakul W; Jirajariyavej S; Kantipong P; Prasithsirikul W; Sungkanuparph S; Bowonwatanuwong C; Klinbuayaem V; Kerr SJ; Sophonphan J; Bhakeecheep S; Hirschel B; Ruxrungtham K;
    Antivir Ther; 2012; 17(7):1351-61. PubMed ID: 23075703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Positioning of lopinavir/ritonavir in antiretroviral treatment schemes].
    Camacho Á; Rivero A
    Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():31-4. PubMed ID: 25542874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Different kinetics of immunologic recovery using nelfinavir or lopinavir/ritonavir-based regimens in children with perinatal HIV-1 infection.
    De Luca M; Miccinesi G; Chiappini E; Zappa M; Galli L; De Martino M
    Int J Immunopathol Pharmacol; 2005; 18(4):729-35. PubMed ID: 16388722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV Viral Dynamics of Lopinavir/Ritonavir Monotherapy as Second-Line Treatment: A Prospective, Single-Arm Trial.
    Claassen CW; Keckich D; Nwizu C; Abimiku A; Salami D; Obiefune M; Gilliam BL; Amoroso A
    J Int Assoc Provid AIDS Care; 2019; 18():2325958218823209. PubMed ID: 30798695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Community Based Antiretroviral Treatment in Rural Zimbabwe.
    Chimukangara B; Manasa J; Mitchell R; Nyabadza G; Katzenstein D; Masimirembwa C
    AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1185-1191. PubMed ID: 28899102
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir.
    Delaugerre C; Teglas JP; Treluyer JM; Vaz P; Jullien V; Veber F; Rouzioux C; Chaix ML; Blanche S
    J Acquir Immune Defic Syndr; 2004 Oct; 37(2):1269-75. PubMed ID: 15385734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A pilot study of switch to lopinavir/ritonavir (LPV/r) monotherapy from nonnucleoside reverse transcriptase inhibitor-based therapy.
    Pierone G; Mieras J; Bulgin-Coleman D; Kantor C; Shearer J; Fontaine L; Fath M; Norton M
    HIV Clin Trials; 2006; 7(5):237-45. PubMed ID: 17162317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial.
    Cahn P; Andrade-Villanueva J; Arribas JR; Gatell JM; Lama JR; Norton M; Patterson P; Sierra Madero J; Sued O; Figueroa MI; Rolon MJ;
    Lancet Infect Dis; 2014 Jul; 14(7):572-80. PubMed ID: 24783988
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short Communication: Efficacy and Safety of Treatment Simplification to Lopinavir/Ritonavir or Darunavir/Ritonavir Monotherapy: A Randomized Clinical Trial.
    Santos JR; Llibre JM; Bravo I; García-Rosado D; Cañadas MP; Pérez-Álvarez N; Paredes R; Clotet B; Moltó J
    AIDS Res Hum Retroviruses; 2016 May; 32(5):452-5. PubMed ID: 26781004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simplifying antiretroviral therapy to lopinavir/ritonavir monotherapy did not improve quality of life and therapy adherence in pretreated HIV-infected children.
    Bunupuradah T; Panthong A; Kosalaraksa P; Wongsabut J; Puthanakit T; Lumbiganon P; Chuanjaroen T; Sopharak C; Udompanit T; Prasitsuebsai W; Pancharoen C; Ananworanich J;
    AIDS Res Hum Retroviruses; 2014 Mar; 30(3):260-5. PubMed ID: 24274723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protease inhibitor resistance in South African children with virologic failure.
    van Zyl GU; van der Merwe L; Claassen M; Cotton MF; Rabie H; Prozesky HW; Preiser W
    Pediatr Infect Dis J; 2009 Dec; 28(12):1125-7. PubMed ID: 19779394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.